120 related articles for article (PubMed ID: 31917466)
1. Propafenone analogue with additional H-bond acceptor group shows increased inhibitory activity on P-glycoprotein.
Cseke A; Schwarz T; Jain S; Decker S; Vogl K; Urban E; Ecker GF
Arch Pharm (Weinheim); 2020 Mar; 353(3):e1900269. PubMed ID: 31917466
[TBL] [Abstract][Full Text] [Related]
2. Intramolecular distribution of hydrophobicity influences pharmacological activity of propafenone-type MDR modulators.
Pleban K; Hoffer C; Kopp S; Peer M; Chiba P; Ecker GF
Arch Pharm (Weinheim); 2004 Jun; 337(6):328-34. PubMed ID: 15188222
[TBL] [Abstract][Full Text] [Related]
3. Structure-activity relationships, ligand efficiency, and lipophilic efficiency profiles of benzophenone-type inhibitors of the multidrug transporter P-glycoprotein.
Jabeen I; Pleban K; Rinner U; Chiba P; Ecker GF
J Med Chem; 2012 Apr; 55(7):3261-73. PubMed ID: 22452412
[TBL] [Abstract][Full Text] [Related]
4. Structure-activity relationship studies of propafenone analogs based on P-glycoprotein ATPase activity measurements.
Schmid D; Ecker G; Kopp S; Hitzler M; Chiba P
Biochem Pharmacol; 1999 Nov; 58(9):1447-56. PubMed ID: 10513988
[TBL] [Abstract][Full Text] [Related]
5. Subtle Structural Differences Trigger Inhibitory Activity of Propafenone Analogues at the Two Polyspecific ABC Transporters: P-Glycoprotein (P-gp) and Breast Cancer Resistance Protein (BCRP).
Schwarz T; Montanari F; Cseke A; Wlcek K; Visvader L; Palme S; Chiba P; Kuchler K; Urban E; Ecker GF
ChemMedChem; 2016 Jun; 11(12):1380-94. PubMed ID: 26970257
[TBL] [Abstract][Full Text] [Related]
6. Exhaustive sampling of docking poses reveals binding hypotheses for propafenone type inhibitors of P-glycoprotein.
Klepsch F; Chiba P; Ecker GF
PLoS Comput Biol; 2011 May; 7(5):e1002036. PubMed ID: 21589945
[TBL] [Abstract][Full Text] [Related]
7. Interaction field based and hologram based QSAR analysis of propafenone-type modulators of multidrug resistance.
Kaiser D; Smiesko M; Kopp S; Chiba P; Ecker GF
Med Chem; 2005 Sep; 1(5):431-44. PubMed ID: 16787327
[TBL] [Abstract][Full Text] [Related]
8. Lead identification for modulators of multidrug resistance based on in silico screening with a pharmacophoric feature model.
Langer T; Eder M; Hoffmann RD; Chiba P; Ecker GF
Arch Pharm (Weinheim); 2004 Jun; 337(6):317-27. PubMed ID: 15188221
[TBL] [Abstract][Full Text] [Related]
9. Synthesis and pharmacological activity of the stereoisomers of GP-88, a propafenone-type modulator of multidrug resistance.
Chiba P; Rebitzer S; Richter E; Hitzler M; Ecker G
Bioorg Med Chem Lett; 1998 Apr; 8(7):829-32. PubMed ID: 9871549
[TBL] [Abstract][Full Text] [Related]
10. A combined Hansch/Free-Wilson approach as predictive tool in QSAR studies on propafenone-type modulators of multidrug resistance.
Tmej C; Chiba P; Huber M; Richter E; Hitzler M; Schaper KJ; Ecker G
Arch Pharm (Weinheim); 1998; 331(7-8):233-40. PubMed ID: 9747179
[TBL] [Abstract][Full Text] [Related]
11. Synthesis, biological evaluation and 3D-QSAR studies of new chalcone derivatives as inhibitors of human P-glycoprotein.
Parveen Z; Brunhofer G; Jabeen I; Erker T; Chiba P; Ecker GF
Bioorg Med Chem; 2014 Apr; 22(7):2311-9. PubMed ID: 24613626
[TBL] [Abstract][Full Text] [Related]
12. Homology Modeling of the Human P-glycoprotein (ABCB1) and Insights into Ligand Binding through Molecular Docking Studies.
Mora Lagares L; Minovski N; Caballero Alfonso AY; Benfenati E; Wellens S; Culot M; Gosselet F; Novič M
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517082
[TBL] [Abstract][Full Text] [Related]
13. Grid-independent Descriptors (GRIND) Analysis and SAR Guided Molecular Docking Studies to Probe Selectivity Profiles of Inhibitors of Multidrug Resistance Transporters ABCB1 and ABCG2.
Shafi T; Jabeen I
Curr Cancer Drug Targets; 2017; 17(2):177-190. PubMed ID: 27585695
[TBL] [Abstract][Full Text] [Related]
14. Self-organizing maps for identification of new inhibitors of P-glycoprotein.
Kaiser D; Terfloth L; Kopp S; Schulz J; de Laet R; Chiba P; Ecker GF; Gasteiger J
J Med Chem; 2007 Apr; 50(7):1698-702. PubMed ID: 17352460
[TBL] [Abstract][Full Text] [Related]
15. Targeting drug-efflux pumps -- a pharmacoinformatic approach.
Pleban K; Kaiser D; Kopp S; Peer M; Chiba P; Ecker GF
Acta Biochim Pol; 2005; 52(3):737-40. PubMed ID: 16082413
[TBL] [Abstract][Full Text] [Related]
16. Pore-exposed tyrosine residues of P-glycoprotein are important hydrogen-bonding partners for drugs.
Dönmez Cakil Y; Khunweeraphong N; Parveen Z; Schmid D; Artaker M; Ecker GF; Sitte HH; Pusch O; Stockner T; Chiba P
Mol Pharmacol; 2014 Mar; 85(3):420-8. PubMed ID: 24366667
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein recognition of substrates and circumvention through rational drug design.
Raub TJ
Mol Pharm; 2006; 3(1):3-25. PubMed ID: 16686365
[TBL] [Abstract][Full Text] [Related]
18. Multispecificity of drug transporters: probing inhibitor selectivity for the human drug efflux transporters ABCB1 and ABCG2.
Cramer J; Kopp S; Bates SE; Chiba P; Ecker GF
ChemMedChem; 2007 Dec; 2(12):1783-8. PubMed ID: 17994597
[TBL] [Abstract][Full Text] [Related]
19. Computational models for identifying potential P-glycoprotein substrates and inhibitors.
Crivori P; Reinach B; Pezzetta D; Poggesi I
Mol Pharm; 2006; 3(1):33-44. PubMed ID: 16686367
[TBL] [Abstract][Full Text] [Related]
20. Similarity based SAR (SIBAR) as tool for early ADME profiling.
Klein C; Kaiser D; Kopp S; Chiba P; Ecker GF
J Comput Aided Mol Des; 2002 Nov; 16(11):785-93. PubMed ID: 12825790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
